A total of 108 children aged 4-17 years were randomized to receive 7 days of azithromycin (10 mg/kg/day; maximum, 500 mg/day) or ceftriaxone (75 mg/kg/day; maximum, 2.5 g/day), to assess the efficacy of the agents for the treatment of uncomplicated typhoid fever. Salmonella typhi was isolated from the initial cultures of blood samples from 64 patients. A total of 31 (91%) of the 34 patients treated with azithromycin and 29 (97%) of the 30 patients treated with ceftriaxone were cured ( ). All 64 isolates were susceptible to azithromycin and P 1 .05 ceftriaxone. Of the patients treated with ceftriaxone, 4 subsequently had relapse of their infection. No serious side effects occurred in any study subject. Oral azithromycin administered once daily appears to be effective for the treatment of uncomplicated typhoid fever in children. If these results are confirmed, the agent could be a convenient alternative for the treatment of typhoid fever, especially in individuals in developing countries where medical resources are scarce.
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Typhoid fever, a systemic infection caused by Salmonella typhi and Salmonella paratyphi, is a common and sometimes fatal infection among children living in developing countries, especially such countries in Asia and Africa [1] . For decades, chloramphenicol has been highly effective against S. typhi and S. paratyphi, and it often remains the antibiotic of choice for the treatment of typhoid fever [2, 3] . However, the widespread emergence of multidrug-resistant S. typhi has necessitated the search for other therapeutic options [4] . Fluoroquinolones have proven to be effective; however, to date, they are restricted from routine use in children, and quinolone-resistant strains of S. typhi have begun to be reported [5, 6] . Ceftriaxone, a thirdgeneration cephalosporin, is highly effective against S. typhi and has become the standard of care for the treatment of typhoid fever in many parts of the world [7] . However, because parenteral administration of ceftriaxone is required, the antibiotic is a less-than-ideal treatment alternative.
The recent availability of the azalide class of antibiotics has provided another potential option for the treatment of typhoid fever. Azithromycin, the first azalide evaluated, has in vitro activity against many enteric intracellular pathogens, including S. typhi [8] [9] [10] . Animal models have demonstrated that azithromycin is highly effective against both Salmonella enteritidis and Salmonella typhimurium, with drug efficacy related to the tissue concentration, rather than the serum concentration, of the antibiotic [11, 12] . Studies of human volunteers have shown that neutrophil concentrations of azithromycin are 1100 times the serum concentration of the antibiotic [13] . Five days after a 3-day course of azithromycin was completed, neutrophil concentrations of the drug still exceeded the typical MIC for S. typhi by 120 times, whereas the drug was unmeasurable in the serum [13] .
These encouraging results led us to initiate a trial of azithromycin treatment in humans. Initially, azithromycin was demonstrated, in an open-labeled, nonrandomized trial, to be effective in the treatment of adults with uncomplicated typhoid fever [14] . A subsequent randomized trial demonstrated that azithromycin was as effective as ciprofloxacin for the treatment of uncomplicated typhoid fever in adults [15] . The results of these studies prompted the present study of azithromycin suspension versus ceftriaxone for the treatment of uncomplicated typhoid fever in children.
Patients and Methods
Study site. The Abbassia Fever Hospital is a 1500-bed infectious disease hospital that serves as both the primary infectious disease hospital in Cairo and a referral center for patients with infectious diseases from throughout Egypt.
Study population. Patients coming to the hospital were initially screened in the reception department. During the study period, all children of 4-17 years of age who, according to the reception department physician, had a clinical diagnosis of typhoid fever were admitted to a single ward in the hospital. After admission to the ward, a study physician reevaluated the patients to determine whether they were eligible for enrollment in the study. Eligibility for enrollment required that a subject have a documented fever (temperature, у38.5ЊC) and a history of fever for at least 4 days plus at least 2 of the following criteria: abdominal tenderness, hepatomegaly, splenomegaly, and/or rose spots. Subjects with the following conditions were excluded from the study: allergy to ceftriaxone or erythromycin (or to other macrolides), major complications of typhoid fever (e.g., pneumonia, intestinal hemorrhage or perforation, shock, or coma), inability to swallow oral medication, significant underlying illness (e.g., heart disease, asthma requiring chronic medications, or immunodeficiencies), or treatment within the past 4 days with either study medication or chloramphenicol, trimethoprim-sulfamethoxazole (TMP-SMZ), or ampicillin. Subjects who might be pregnant or who were lactating were also excluded from the study. Parents of children meeting eligibility requirements were asked to have their child enroll in the study, and if they agreed, informed consent was obtained before randomization of the study drug.
Sample size requirements. The study was designed to detect a 50% difference in clinical cure rates between the 2 treatment groups, under the assumption that 80% of the subjects treated with ceftriaxone would respond to therapy, with "response" defined as the patient becoming afebrile within 5 days of starting treatment. Using a type I error rate of 0.05 and a type II error rate of 0.2, it was projected that 30 evaluable subjects (those with positive blood cultures) would be needed in each treatment arm [16] . Historically, ∼50% of patients who are thought, as a result of findings of clinical examination, to have typhoid fever have S. typhi or S. paratyphi isolated from their blood or stool. Thus, enrollment of 60 subjects in each treatment arm was planned for the trial.
Randomization and treatment. To control for age bias, patients were stratified into 3 age groups (4-7 years, 8-12 years, and 13-17 years) before randomization. After study eligibility was determined and informed consent was obtained, patients were randomized to 1 of the 2 treatment groups. Before randomization, sequentially numbered sealed envelopes containing the name of the study agent to be used were created by block randomization that was based on a random list of numbers. At the time of randomization, neither the subject nor the study physician was aware of which study agent would be administered. Treatment assignments were made at enrollment by opening the lowest numbered envelope that had yet to be used for the age group of the child.
After assignment, subjects were treated, in an open-label format, with either oral azithromycin suspension (10 mg/kg/day; maximum dose, 500 mg/day) administered once daily for 7 days or im ceftriaxone (75 mg/kg/day; maximum dose, 2.5 g/day) administered once daily for 7 days. Azithromycin powder was reconstituted with sterile water (according to package guidelines) in a bottle, and the bottle was labeled with the unique identification number of the study subject. After reconstitution, azithromycin was stored at room temperature until it was administered to the study subject. Ceftriaxone powder, which was mixed with 1% lidocaine solution provided by the manufacturer, was administered immediately after reconstitution by means of deep im injection. All medications were administered in the hospital by the nursing staff.
Procedures. Patients enrolled in the study were hospitalized for the entire treatment period and for 3 days after therapy was completed. Before initiation of antibiotic therapy, samples of blood, stool, and urine were cultured. Repeated blood cultures were performed for all subjects 4 and 10 days after treatment was initiated. Repeated stool and urine cultures were performed on day 10 if the initial culture result was positive. All subjects had a stool culture performed 1 month after completion of therapy. A blood sample was obtained for determination of the complete blood cell count and for serum chemistry analysis at baseline and on day 10.
Cultures of blood and stool were processed by means of standard clinical methods. All blood cultures were blindly subcultured after 1, 7, and 14 days of incubation. Subcultures were performed at other times if the broth appeared cloudy. Identification of Salmonella isolates was performed by use of standard methods [17] . Stool specimens were plated on MacConkey agar and SalmonellaShigella agar, and colonies suggestive of Salmonella species were further evaluated by means of standard methods to determine exact identification [17] . All isolates of S. typhi or S. paratyphi were tested for susceptibility to azithromycin, ceftriaxone, ciprofloxacin, chloramphenicol, ampicillin, and TMP-SMZ by means of agar disk diffusion analysis done according to the method of Bauer et al. [18] .
During the period of hospitalization, vital signs (including body temperature) were measured every 8 h, and clinical examination was performed daily. During clinical examination, the general condition of the patient as well as the presence of coated tongue, abdominal tenderness, splenomegaly, hepatomegaly, or rash were specifically noted. In addition, a structured questionnaire was administered daily during hospitalization to record symptomatology (including fever, headache, rash, abdominal pain, constipation, diarrhea, and/or anorexia) and possible adverse events. Subjects were routinely checked at 2 and 4 weeks after completion of treatment and were asked to return immediately if they became sick before a scheduled follow-up visit.
Data analysis. Responses to treatment were classified as clinical cure or failure and as microbiological cure or failure. "Clinical cure" was defined as resolution of all typhoid-related symptoms or signs by the end of 7 days of therapy. For response to therapy, "fever" was defined as у1 rectal temperature 138.4ЊC during a 24-h period. "Clinical failure" was defined either as persistence of у1 typhoid-related symptoms or signs present at study entry, or as development of a typhoid-related complication (including pneumonia, intestinal hemorrhage or perforation, shock, or coma) after at least 4 days of therapy. "Microbiological cure" was defined as a sterile blood culture on days 4 and 10 of therapy. "Relapse" was defined as recurrence of fever with signs or symptoms of typhoid fever within 4 weeks of completion of therapy along with isolation of S. typhi or S. paratyphi from the blood. The x 2 test was used to determine significant differences in cure rates between groups. For groups with !5 events in a cell, Fisher's exact test was used.
Results
A total of 108 patients (53 males and 55 females; mean , years) were enrolled in the study and asage ‫ע‬ SD 9.8 ‫ע‬ 2.8 signed to a treatment arm. Cultures of blood specimens obtained from 64 children (34 azithromycin recipients and 30 ceftriaxone recipients) were positive for S. typhi; these subjects were included in the analysis.
Demographic and pretreatment laboratory evaluation of the subjects demonstrated that there were no significant differences between the treatment groups (table 1). Antimicrobial susceptibility testing showed that all 64 blood culture isolates of S. typhi were susceptible to azithromycin, ceftriaxone, and ciprofloxacin.
Responses to treatment were excellent in both groups (table  2) . Patients responded quickly to therapy; the mean time to defervescence ‫ע‬ SD was days and days for 4.1 ‫ע‬ 1.1 3.9 ‫ע‬ 1.0 azithromycin recipients and ceftriaxone recipients, respectively ( ). Clinical cure occurred in 31 (91%) of 34 patients P p NS treated with azithromycin, compared with 29 (97%) of 30 patients treated with ceftriaxone ( ). Of the 3 patients with P p NS clinical failure in the azithromycin group, 2 had failure as a result of slow resolution of fever without other symptoms. All 3 subjects received ceftriaxone for an additional 5-7 days after they had received azithromycin for 7 days; all 3 had complete cures without any significant consequences.
Microbiological cure occurred in 33 (97%) of 34 patients treated with azithromycin versus 29 (97%) of 30 patients treated with ceftriaxone ( ). The patient with microbiological P p NS failure in the azithromycin group had S. typhi isolated from blood on both day 4 and day 10, whereas the patient with microbiological failure in the ceftriaxone group had S. typhi isolated from blood on day 10. Both patients with microbiological failure also had clinical failure. Another course of antibiotics (ceftriaxone for the subject who initially received azithromycin and chloramphenicol for the subject who initially received ceftriaxone) was administered to both subjects after they had received initial therapy for 7 days. For both subjects, the second course of antibiotics was clinically successful.
After discharge from the hospital, 58 subjects (30 of 34 azithromycin recipients and 28 of 30 ceftriaxone recipients) who had S. typhi initially isolated from their blood returned for posttreatment follow-up evaluation. Six of the 30 subjects treated with ceftriaxone returned before the scheduled 1-month followup evaluation because of recurrence of typhoid-related symptoms; S. typhi was isolated from blood specimens from 4 of these patients. All 6 subjects were treated with a second course of antibiotics that resulted in resolution of their symptoms and sterile posttreatment blood cultures. No relapses occurred in the group treated with azithromycin. With the exception of the 6 subjects described above, all patients were clinically well when they returned for evaluation 1 month after completion of therapy. Antimicrobial susceptibility testing demonstrated that all 8 of the S. typhi isolates from children who had relapses or for whom treatment failed remained susceptible to all antibiotics tested.
No subject had a serious adverse event. Gastrointestinal symptoms were commonly reported by both groups. Vomiting occurred more frequently in subjects treated with azithromycin than in those treated with ceftriaxone; however, the symptom was mild and transient, resolving, in most cases, within 1 day of initiation of treatment with azithromycin. In no case was the symptom severe enough to require treatment or alteration of antibiotic therapy. Pain at the site of injection, the most common adverse event in the ceftriaxone group, was typically mild; however, 6 subjects complained of pain up to 24 hours after injection, despite both the mixture of lidocaine with ceftriaxone before injection and the rotation of injection sites. With the exception of 1 patient from each group who had a mild, residual elevation of alanine aminotransferase concentration, all subjects with abnormal results of pretreatment laboratory analysis had normal values at the end of therapy. Blood evaluation on day 10 revealed that 4 patients in the azithromycin group and 3 patients in the ceftriaxone group had thrombocytosis (platelet count, 1500,000 cells/mm 3 ), but all subjects were asymptomatic. In addition, 4 subjects treated with ceftriaxone and 2 subjects treated with azithromycin developed mild, asymptomatic elevations in aspartate aminotransferase concentrations (range, 110-170 U/L) during the course of therapy.
Discussion
In a comparative, randomized trial, we demonstrated that azithromycin is highly effective for the treatment of uncomplicated typhoid fever in children. In the present study, findings of clinical cure rates 190% and microbiological cure rates 195% for subjects receiving either azithromycin or ceftriaxone compare favorably with findings from past trials of standard antibiotics for the treatment of typhoid fever [2, 6, [19] [20] [21] . It is interesting that, in the present study, 14% of subjects with bacteremia who were treated with ceftriaxone had relapses of infection within 1 month of completion of therapy. These data are consistent with relapse rates of 5%-15% in other trials of ceftriaxone for the treatment of typhoid fever [2, 7, 19, 22] . Although our sample size was small, no subject who was treated with azithromycin had a relapse; this finding may be attributable to the long half-life of azithromycin within the intracellular compartment, with eradication of residual organisms after completion of therapy, as well as to its elevated concentration within the biliary system. The extremely long half-life of azithromycin in tissue, in conjunction with the success of the drug in the present trial, may warrant trials in which shorter courses of this agent are used for the treatment of typhoid fever, as have been successfully tried for quinolone antibiotics [6, 19, 23] .
Clinical differences between the 2 treatment groups were few.
Patients treated with ceftriaxone had a slightly shorter time to defervescence than did those treated with azithromycin (3.9 vs. 4.1 days, respectively); however, the difference was not significant, and both results were within time frames reported in previous typhoid treatment trials [3, 19, [23] [24] [25] . Mild and transient gastrointestinal symptoms occurred in both treatment groups, but no adverse event was severe enough to require alteration in therapy.
In conclusion, azithromycin given for 7 days at a dosage of 10 mg/kg/day (maximum dose, 500 mg/day) appears to be highly effective for the treatment of uncomplicated typhoid fever in children, with clinical cure rates comparable to those for ceftriaxone. Once-daily administration of oral azithromycin may offer a simple treatment regimen for typhoid fever caused by either susceptible or drug-resistant strains of S. typhi and may be suitable for use in areas where medical resources are limited.
